scorecardresearch
Follow Us:
Saturday, May 28, 2022

Cadila Healthcare Q4 net profit declines 15 per cent at Rs 392 crore

The company had posted a net profit of Rs 460.1 crore for the corresponding period of 2018-19, Cadila Healthcare said in a BSE filing.

By: PTI | New Delhi |
June 19, 2020 5:31:36 pm
Net profit of the company for the fiscal ended March this year was Rs 1,176.6 crore as against Rs 1,848.8 crore for the previous fiscal, Cadila Healthcare said. (Representational image)

Drug firm Cadila Healthcare on Friday reported a 14.82 per cent decline in consolidated net profit to Rs 391.90 crore for the quarter ended on March 31, 2020.

The company had posted a net profit of Rs 460.1 crore for the corresponding period of 2018-19, Cadila Healthcare said in a BSE filing.

Total revenue from operations stood at Rs 3,752.1 crore for the quarter under consideration. It was Rs 3,732.8 crore for the same period year ago, it added.

Net profit of the company for the fiscal ended March this year was Rs 1,176.6 crore as against Rs 1,848.8 crore for the previous fiscal, Cadila Healthcare said.

Best of Express Premium

Weekly Horoscope, May 29, 2022 – June 4, 2022: Libra, Aries, Pisces and o...Premium
Heat rising over Kerala rally, PFI in no mood to backtrack on ‘camp...Premium
‘Monetisation’ axed, MeitY’s fresh draft to ‘encourage’ cos to share non-...Premium
Supreme Court directions on sex workers: history of the case, and where i...Premium

The company’s consolidated total revenue from operations stood at Rs 14,253.1 crore for FY20. It was Rs 13,165.6 crore for FY19, it added.

Strengthening its regulatory pipeline, the company filed 30 additional abbreviated new drug applications (ANDAs) during the year with USFDA, taking the cumulative filings to 390. The company received 28 ANDA approvals during the year, taking the total to 282 product approvals, Cadila Healthcare said.

“During the year, the company launched the oral anti-diabetic agent, Vinglyn (vildagliptin) and Vinglyn M (vildagliptin plus metformin) in India, Vinglyn is now one of the most affordable brands of vildagliptin for diabetic patients in India,” it added.

Shares of Cadila Healthcare were trading at Rs 361.95 per scrip on the BSE, down 1 per cent over previous close.

For all the latest Business News, download Indian Express App.

  • Newsguard
  • The Indian Express website has been rated GREEN for its credibility and trustworthiness by Newsguard, a global service that rates news sources for their journalistic standards.
  • Newsguard
Advertisement
Advertisement
Advertisement
Advertisement